3.1.3.5 (2E)-5-(5-methylfuran-2-yl)-N-(2-methylphenyl)-3-oxo-2-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide 67% inhibition at 0.005 mM 230611 3.1.3.5 (2R,4S,5R)-1-[5-(2-fluoro-2-phosphonoethyl)tetrahydro-4-hydroxy-2-furyl]thymine - 99658 3.1.3.5 (2R,4S,5R)-1-[tetrahydro-4-hydroxy-5-(2-phosphonoethyl)-2-furyl]thymine - 99659 3.1.3.5 (2R,5R)-1-[5-(2-fluoro-2-phosphonoethyl)tetrahydro-2-furyl]thymine - 99660 3.1.3.5 (2R,5S)-1-[tetrahydro-5-(2-phosphonoethyl)-2-furyl]thymine - 99661 3.1.3.5 (2Z)-2-[[3-(3-fluoro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl]methylidene]-6-[(4-methylphenyl)methyl]-7H-[1,3]thiazolo[3,2-b][1,2,4]triazine-3,7(2H)-dione 61% inhibition at 0.005 mM 230641 3.1.3.5 1,10-phenanthroline inhibition of cytosolic and membrane-bound enzyme 62 3.1.3.5 1-(6-deoxy-6-phosphono-beta-D-allofuranosyl)-5-(2-(E)-phenylvinyl)-cytosine - 197264 3.1.3.5 1-(6-deoxy-6-phosphono-beta-D-allofuranosyl)-5-phenyl-cytosine - 197263 3.1.3.5 1-(6-deoxy-6-phosphono-beta-D-allofuranosyl)-cytosine - 197262 3.1.3.5 1-amino-2-methyl-4-(phenylamino)anthracene-9,10-dione 4% inhibition at 1 mM 159010 3.1.3.5 1-amino-4-(1-anthracenylamino)-9,10-dioxo-9,10 dihydroanthracene-2-sulfonate - 78872 3.1.3.5 1-amino-4-(1-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate competitive mechanism 79165 3.1.3.5 1-amino-4-(2,3-dimethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 39% inhibition at 1 mM 159020 3.1.3.5 1-amino-4-(2,4-dimethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 47% inhibition at 1 mM 159019 3.1.3.5 1-amino-4-(2,5-dimethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 26% inhibition at 1 mM 158848 3.1.3.5 1-amino-4-(2-aminophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 47% inhibition at 1 mM 159011 3.1.3.5 1-amino-4-(2-anthracenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate competitive mechanism 79310 3.1.3.5 1-amino-4-(2-carboxy-4-chlorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 52% inhibition at 1 mM 159017 3.1.3.5 1-amino-4-(2-carboxy-4-fluorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79007 3.1.3.5 1-amino-4-(2-carboxy-5-chlorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 27% inhibition at 1 mM 159016 3.1.3.5 1-amino-4-(2-carboxy-5-fluorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 60% inhibition at 1 mM 159018 3.1.3.5 1-amino-4-(2-carboxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 78860 3.1.3.5 1-amino-4-(2-ethoxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 56% inhibition at 1 mM 158798 3.1.3.5 1-amino-4-(2-hydroxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79312 3.1.3.5 1-amino-4-(2-methoxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 9% inhibition at 1 mM 158782 3.1.3.5 1-amino-4-(2-methyl-1-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 78881 3.1.3.5 1-amino-4-(2-methylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 33% inhibition at 1 mM 158918 3.1.3.5 1-amino-4-(2-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79297 3.1.3.5 1-amino-4-(2-sulfophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 14% inhibition at 1 mM 158999 3.1.3.5 1-amino-4-(3,4-dimethoxyphenethylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 44% inhibition at 1 mM 159001 3.1.3.5 1-amino-4-(3-amino-2,4,6-trimethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 78830 3.1.3.5 1-amino-4-(3-amino-4-sulfophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79299 3.1.3.5 1-amino-4-(3-amino-5-carboxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 44% inhibition at 1 mM 158986 3.1.3.5 1-amino-4-(3-aminophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 31% inhibition at 1 mM 159000 3.1.3.5 1-amino-4-(3-carboxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 26% inhibition at 1 mM 158788 3.1.3.5 1-amino-4-(3-methylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79293 3.1.3.5 1-amino-4-(4-amino-3-sulfophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79294 3.1.3.5 1-amino-4-(4-aminophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79292 3.1.3.5 1-amino-4-(4-bromo-2-carboxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 56% inhibition at 1 mM 158862 3.1.3.5 1-amino-4-(4-bromophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79081 3.1.3.5 1-amino-4-(4-carboxymethylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 26% inhibition at 1 mM 158922 3.1.3.5 1-amino-4-(4-chlorophenethylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 62% inhibition at 1 mM 158997 3.1.3.5 1-amino-4-(4-chlorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79002 3.1.3.5 1-amino-4-(4-ethoxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 31% inhibition at 1 mM 158814 3.1.3.5 1-amino-4-(4-fluorophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79303 3.1.3.5 1-amino-4-(4-hydroxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79304 3.1.3.5 1-amino-4-(4-methylphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79008 3.1.3.5 1-amino-4-(4-phenoxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79302 3.1.3.5 1-amino-4-(4-phenylaminophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 37% inhibition at 1 mM 159009 3.1.3.5 1-amino-4-(4-sulfophenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79306 3.1.3.5 1-amino-4-(5-sulfo-1-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 78851 3.1.3.5 1-amino-4-(6-carboxy-2-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79305 3.1.3.5 1-amino-4-(6-sulfo-1-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79296 3.1.3.5 1-amino-4-(8-sulfo-1-naphthylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 79075 3.1.3.5 1-amino-4-(9-phenanthrenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 58% inhibition at 1 mM 159003 3.1.3.5 1-amino-4-(benzylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 43% inhibition at 1 mM 159004 3.1.3.5 1-amino-4-(cyclohexylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate - 78832 3.1.3.5 1-amino-4-(cyclopentylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 51% inhibition at 1 mM 158889 3.1.3.5 1-amino-4-(isopropylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 15% inhibition at 1 mM 159007 3.1.3.5 1-amino-4-(phenethylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 53% inhibition at 1 mM 159005 3.1.3.5 1-amino-4-bromo-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid - 197267 3.1.3.5 1-amino-4-[4-(diethoxyphosphoryl)methylphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 28% inhibition at 1 mM 158850 3.1.3.5 1-pentyl-1H-benzofuro[3,2-b]pyrrolo[3,2-e]pyridine-3-carbonitrile - 230864 3.1.3.5 1-tert-butyl-1H-benzofuro[3,2-b]pyrrolo[3,2-e]pyridine-3-carbonitrile - 230865 3.1.3.5 1-tert-butyl-5-chloro-6-(2-hydroxy-5-methylphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile - 230866 3.1.3.5 1-tert-butyl-5-chloro-6-(2-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile - 230867 3.1.3.5 2'-AMP - 771 3.1.3.5 2,2'-(2-(2-((2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-carboxamido)ethylamino)-2-oxoethylazanediyl) diacetic acid nucleotide-derived inhibitor 197268 3.1.3.5 2,3,5-tri-O-benzyl-1-O-(4-nitrobenzoyl)-D-arabinofuranose 68% inhibition at 0.005 mM 230906 3.1.3.5 2-((4'-cyano-4,4''-dimethoxy-[1,1':3',1''-terphenyl]-5'-yl)thio)-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)acetamide 73% inhibition at 0.005 mM 230918 3.1.3.5 2-(3,4-dihydroisoquinolin-2(1H)-yl)-N-[4-[1-(4-methylbenzoyl)-2,3-dihydro-1H-indol-5-yl]-5-sulfanyl-1,3-thiazol-2-yl]acetamide 74% inhibition at 0.005 mM 230948 3.1.3.5 2-(3-methyl-1,5-diphenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol - 230967 3.1.3.5 2-(5-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methylphenol - 231007 3.1.3.5 2-(5-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-5-methoxyphenol - 231008 3.1.3.5 2-(5-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol - 231009 3.1.3.5 2-(5-chloro-3-methyl-1-p-tolyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methylphenol - 231010 3.1.3.5 2-(5-chloro-3-methyl-1-p-tolyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol - 231011 3.1.3.5 2-(5-chloro-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-methylphenol - 231012 3.1.3.5 2-(5-chloro-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-5-methoxyphenol - 231013 3.1.3.5 2-(5-chloro-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol - 231014 3.1.3.5 2-chloro-N-(pyridin-4-yl)benzamide - 231044 3.1.3.5 2-fluoroadenine-9-beta-D-arabinofuranoside 1 mM, 70% inhibition with 5 mM 5'-AMP as substrate 117577 3.1.3.5 2-mercaptoethanol - 63 3.1.3.5 2-methyl-N-(pyridin-4-yl)benzamide - 231056 3.1.3.5 2-nitro-N-(pyridin-4-yl)benzamide - 231062 3.1.3.5 2-phenyl-N-(pyridin-4-yl)acetamide - 231067 3.1.3.5 3'-AMP - 652 3.1.3.5 3,4,5-trimethoxy-N-(pyridin-4-yl)benzamide - 231116 3.1.3.5 3,5-dinitro-N-(pyridine-4-yl)benzamide - 231119 3.1.3.5 3,8-dimethyl-1-p-tolyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine - 231120 3.1.3.5 3,8-dimethyl-1-phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine - 231121 3.1.3.5 3-(2-(3,4,5-trimethoxybenzylideneamino)thiazol-4-yl)-2Hchromen-2-one - 231148 3.1.3.5 3-(2-(3-chlorobenzylideneamino)thiazol-4-yl)-2H-chromen-2-one - 231149 3.1.3.5 3-(2-(3-methoxy-4-phenoxybenzylideneamino)thiazol-4-yl)-2H-chromen-2-one - 231150 3.1.3.5 3-(2-(3-nitrobenzylideneamino)thiazol-4-yl)-2H-chromen-2-one - 231151 3.1.3.5 3-(2-(4-bromobenzylideneamino)thiazol-4-yl)-2H-chromen-2-one - 231152 3.1.3.5 3-(2-(4-chlorobenzylideneamino)thiazol-4-yl)-2H-chromen-2-one - 231153 3.1.3.5 3-(2-(4-fluorobenzylideneamino)thiazol-4-yl)-2H-chromen-2-one - 231154 3.1.3.5 3-(2-(furan-2-ylmethyleneamino)thiazol-4-yl)-2H-chromen-2-one - 231156 3.1.3.5 3-chloro-N-(pyridin-4-yl)benzamide - 231231 3.1.3.5 3-methyl-1-p-tolyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine - 231309 3.1.3.5 3-methyl-1-phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine - 231310 3.1.3.5 3-methyl-N-(pyridin-4-yl)benzamide - 231311 3.1.3.5 3-nitro-N-(pyridin-4-yl)benzamide - 231313 3.1.3.5 3-[4,5-di([1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl]-1H-indole 93% inhibition at 0.005 mM 231339 3.1.3.5 4-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonic acid compound shows high cytotoxicity on H157 cells, with about 72% at 100 mM final concentration 197266 3.1.3.5 4-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonic acid - 197266 3.1.3.5 4-(4-[1-[(3-chlorophenyl)methyl]-4-hydroxy-1H-[1,2,3]triazolo[4,5-c]pyridin-6-yl]piperidine-1-sulfonyl)-N-cycloheptylbenzene-1-sulfonamide 63% inhibition at 0.005 mM 231419 3.1.3.5 4-(6-[[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methyl]-1H-benzimidazol-2-yl)aniline 78% inhibition at 0.005 mM 231422 3.1.3.5 4-chloro-N-(pyridin-4-yl)benzamide - 231471 3.1.3.5 4-methyl-N-(pyridin-4-yl)benzamide - 231481 3.1.3.5 4-nitro-N-(pyridin-4-yl)benzamide - 231482 3.1.3.5 4-nitrophenyl phosphate - 136 3.1.3.5 5'-AMP - 236 3.1.3.5 5'-deoxy-5'-S-isobutylthioadenosine - 91803 3.1.3.5 5'-deoxy-7-methyl-5'-(4-phosphono-1H-pyrazol-1-yl)guanosine moderately potent inhibitor 231510 3.1.3.5 5-chloro-3-methyl-1-phenyl-6-(2-propoxyphenyl)-1H-pyrazolo[3,4-b]pyridine - 231527 3.1.3.5 5-chloro-6-(2-(heptyloxy)phenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine - 231528 3.1.3.5 5-chloro-6-(2-hydroxy-5-methylphenyl)-2-phenyl-2H-pyrazolo[3,4-b]pyridin-3-ol - 231529 3.1.3.5 5-chloro-6-(2-hydroxyphenyl)-2-phenyl-2H-pyrazolo[3,4-b]pyridin-3-ol - 231530 3.1.3.5 5-chloro-6-(2-methoxyphenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine - 231531 3.1.3.5 5-ethynyl-2',3'-dideoxyuridine - 99900 3.1.3.5 5-ethynyldideoxyuridine selective inhibitor 66177 3.1.3.5 6-(4-ethoxyphenyl)-3-(4-methylphenyl)-N-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 65% inhibition at 0.005 mM 231621 3.1.3.5 6-amino-4-hydroxynaphthalene-2-sulfonic acid most potent inhibitor of the screen 197265 3.1.3.5 6-chloro-7-(2-hydroxy-5-methylphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione - 231657 3.1.3.5 6-chloro-7-(2-hydroxyphenyl)-1-methylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione - 231658 3.1.3.5 6-chloro-7-(2-hydroxyphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione - 231659 3.1.3.5 6-Chloropurine riboside - 6470 3.1.3.5 6-gamma,gamma-dimethylallylaminopurine riboside - 111960 3.1.3.5 6-mercaptopurine riboside - 7132 3.1.3.5 6-N,N-diethyl-D-beta-gamma-dibromomethylene adenosine triphosphate originally named FPL 67156 or ARL 67156, 28% inhibition at 0.1 mM 138806 3.1.3.5 6-Thiopurine - 12401 3.1.3.5 7-methoxy-3-methyl-1-phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine - 231728 3.1.3.5 adenosine strong inhibition, enzymes N-I and N-II 122 3.1.3.5 adenosine - 122 3.1.3.5 adenosine 5'-(alpha,beta-methylene)diphosphate complete inhibition at 0.1 mM 5513 3.1.3.5 adenosine 5'-(alpha,beta-methylene)diphosphate specific inhibitor, complete inhibition at 0.5 mM 5513 3.1.3.5 adenosine 5'-(alpha,beta-methylene)diphosphate specific CD73 inhibitor 5513 3.1.3.5 adenosine 5'-(alpha,beta-methylene)diphosphate - 5513 3.1.3.5 adenosine 5'-(alpha,beta-methylene)diphosphate competitive inhibitor 5513 3.1.3.5 adenosine 5'-(alpha,beta-methylene)diphosphate treatment with 0.001 mM adenosine 5'-(alpha,beta-methylene)diphosphate, a competitive ecto-5'-NT/CD73 inhibitor, causes a significant reduction of 30% in glioma cell proliferation, the inhibitory effect on cell proliferation caused by adenosine 5'-(alpha,beta-methylene)diphosphate is reverted by cotreatment with nitrobenzylthioinosine and dipyridamole 5513 3.1.3.5 adenosine 5'-(alpha,beta-methylene)diphosphate not inhibitory 5513 3.1.3.5 adenosine 5'-(alpha,beta-methylene)triphosphate - 46072 3.1.3.5 adenosine 5'-sulfate - 9423 3.1.3.5 ADP inhibits eNs 13 3.1.3.5 ADP competitive 13 3.1.3.5 ADP - 13 3.1.3.5 ADP 40% inhibition at 0.1 mM 13 3.1.3.5 ADP competitive inhibitor 13 3.1.3.5 ADP feed-forward inhibition 13 3.1.3.5 ADP moderately potent inhibitor 13 3.1.3.5 agglutinin cytosolic enzyme 31358 3.1.3.5 agglutinin plasma membrane enzyme 31358 3.1.3.5 agglutinin enzyme from glioblastoma cells 31358 3.1.3.5 alpha,beta-methylene adenosine 5'-diphosphate specific inhibitor 138802 3.1.3.5 alpha,beta-methylene adenosine diphosphate 0.1 mM 138804 3.1.3.5 alpha,beta-methylene adenosine-5'-diphosphate - 138803 3.1.3.5 alpha,beta-methylene ADP - 163515 3.1.3.5 alpha,beta-methylene-ADP 0.1 mM, 58% residual activity 7144 3.1.3.5 alpha,beta-methylene-ADP - 7144 3.1.3.5 alpha,beta-methylene-ADP highly effective competitive inhibitor 7144 3.1.3.5 alpha,beta-methylene-ADP a specific CD73 inhibitor 7144 3.1.3.5 alpha,beta-methylene-ADP specific inhibitor 7144 3.1.3.5 alpha,beta-methylene-ADP competitive inhibitor 7144 3.1.3.5 alpha-beta-methylene-ADP - 232725 3.1.3.5 alpha/beta-methylene-ADP a specific CD73 inhibitor 85251 3.1.3.5 alphabeta-methylene ADP 0.05 mM 138801 3.1.3.5 Ammonium molybdate almost complete inhibition at 1.0 mM 3327 3.1.3.5 Ammonium molybdate 17.6% residual activity at 0.1 mM ammonium molybdate 3327 3.1.3.5 Ammonium molybdate - 3327 3.1.3.5 Ap[CH2]p mixed competitive inhibitor 33699 3.1.3.5 araCMP 1 mM, 25% inhibition with 5 mM 5'-AMP as substrate 9652 3.1.3.5 ATP inhibits eNs, no effect on cNI 4 3.1.3.5 ATP competitive 4 3.1.3.5 ATP - 4 3.1.3.5 ATP 70% inhibition at 0.1 mM 4 3.1.3.5 ATP competitive inhibitor 4 3.1.3.5 ATP feed-forward inhibition 4 3.1.3.5 ATP inhibition at substrate concentration above 6 mM 4 3.1.3.5 B4O72- - 47070 3.1.3.5 benzoic acid inhibition of cytosolic enzyme 498 3.1.3.5 beta-gamma-methylene-ATP - 232724 3.1.3.5 Ca2+ 5 mM, inhibition of both hydrolysis of AMP and ADP 15 3.1.3.5 Ca2+ gradual decrease in enzyme activity in the presence of 1-6 mM of Ca2+ 15 3.1.3.5 Ca2+ 89.5% residual activity at 5 mM 15 3.1.3.5 Ca2+ - 15 3.1.3.5 cAMP - 268 3.1.3.5 Cd2+ - 52 3.1.3.5 CDP - 212 3.1.3.5 Cl- weak inhibition 141 3.1.3.5 clomipramine enzymatic activity is decreased by the antidepressant clomipramine after in vitro exposure 4115 3.1.3.5 Co2+ plasma membrane enzyme 23 3.1.3.5 Co2+ 0.1 mM activate, 4 mM inhibit, plasma membrane enzyme 23 3.1.3.5 Co2+ strong, enzyme from glioblastoma cells 23 3.1.3.5 Co2+ inhibition of cytosolic and membrane-bound enzyme 23 3.1.3.5 concanavalin A - 2045 3.1.3.5 concanavalin A partial non-competitive 2045 3.1.3.5 concanavalin A strong inhibition at 0.02 mg/ml 2045 3.1.3.5 concanavalin A complete inhibition at 0.006 mM 2045 3.1.3.5 concanavalin A strong inhibitor 2045 3.1.3.5 concanavalin A upon blockade of enzyme by concanavalin A, the strength of adhesion to different extracellular matrix proteins is not altered, but at the same time the invasion ability of the cells is decreased 2045 3.1.3.5 concanavalin A strong inhibition 2045 3.1.3.5 concanavalin A cytosolic enzyme 2045 3.1.3.5 concanavalin A plasma membrane enzyme 2045 3.1.3.5 concanavalin A enzyme from glioblastoma cells 2045 3.1.3.5 CTP - 60 3.1.3.5 Cu2+ further inhibition of the residual activity in EDTA-treated enzyme 19 3.1.3.5 Cu2+ 3.9% residual activity at 5 mM 19 3.1.3.5 Cu2+ - 19 3.1.3.5 Cu2+ inhibition of cytosolic and membrane-bound enzyme 19 3.1.3.5 Cys-Gly - 2436 3.1.3.5 cysteamine - 787 3.1.3.5 dADP - 731 3.1.3.5 dATP - 140 3.1.3.5 dCTP - 179 3.1.3.5 deoxyadenosine - 601 3.1.3.5 deoxycytidine - 451 3.1.3.5 dGDP - 1140 3.1.3.5 dGTP - 219 3.1.3.5 dithiothreitol - 45 3.1.3.5 dITP - 2839 3.1.3.5 DTT 1 mM, about 45% inhibition 177 3.1.3.5 dTTP - 145 3.1.3.5 dUTP - 435 3.1.3.5 EDTA restoration of activity by addition of divalent cations: Cu2+, Ni2+, Co2+ or Mg2+ 21 3.1.3.5 EDTA 3 mM, complete inhibition 21 3.1.3.5 EDTA complete inhibition at 1 mM 21 3.1.3.5 EDTA decrease of the enzyme activity in presence of 0.5 mM EDTA 21 3.1.3.5 EDTA 2 mM, 5% residual activity 21 3.1.3.5 EDTA - 21 3.1.3.5 EDTA strong inhibition 21 3.1.3.5 EDTA plasma membrane enzyme 21 3.1.3.5 EDTA inhibition of membrane-bound enzyme 21 3.1.3.5 EDTA inhibition of cytosolic and membrane-bound enzyme 21 3.1.3.5 EGTA - 173 3.1.3.5 ethanol 23% and 28% inhibition at 0.5% and 1% (v/v) ethanol, respectively 69 3.1.3.5 ethyl 4-(2-((4'-cyano-4''-methoxy-4-methyl-[1,1':3',1''-terphenyl]-5'-yl)thio)acetamido)benzoate 80% inhibition at 0.005 mM 231816 3.1.3.5 ethyl 4-(3-hydroxyphenyl)-6-methyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidine-5-carboxylate monastrol 230380 3.1.3.5 ethyl 4-[4-(dimethylamino)phenyl]-6-methyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidine-5-carboxylate LaSOM 63 230382 3.1.3.5 Fe2+ the enzyme is susceptible to Fe2+-ion catalyzed oxidative modification. Among the examined chelators it is only deferoxamine and Na-citrate that exert a fully protective and reactivating ability, among the antioxidants it is only GSH, among the metal cations it is only Mn2+ 25 3.1.3.5 Fe2+ oxidative inactivation in a Fe2+/GSH system may be related to the selective association of Fe2+ and thiols to the enzyme molecule 25 3.1.3.5 Fe2+ further inhibition of the residual activity in EDTA-treated enzyme 25 3.1.3.5 Fe2+ plasma membrane enzyme 25 3.1.3.5 Fe3+ 3.3% residual activity at 5 mM 70 3.1.3.5 Fe3+ enzyme N-I and N-II 70 3.1.3.5 fluoxetine chronic treatment with 10mg/kg fluoxetine causes a 42% inhibition of AMP hydrolysis 4645 3.1.3.5 fluoxetine - 4645 3.1.3.5 gamma-glutamylcysteine - 5548 3.1.3.5 GDP - 53 3.1.3.5 GSH - 142 3.1.3.5 GTP - 37 3.1.3.5 Hg2+ - 33 3.1.3.5 HgCl2 1 mM, about 20% inhibition 110 3.1.3.5 HgCl2 63% inhibition at 1 mM, decreases AMP hydrolysis in a non-competitive manner 110 3.1.3.5 IDP - 444 3.1.3.5 Inosine strong inhibition, enzymes N-I and N-II 167 3.1.3.5 ITP - 229 3.1.3.5 KCl - 79 3.1.3.5 kinstin riboside - 100776 3.1.3.5 L-arginine 21% inhibition at 0.1 mM 123 3.1.3.5 L-ascorbic acid inhibition of cytosolic enzyme 974 3.1.3.5 L-cysteine - 74 3.1.3.5 L-cysteine ethyl ester - 12802 3.1.3.5 levamisole 1 mM, 81% residual activity 3477 3.1.3.5 Ly-294002 0.01 mM LY-294002 abolishes lipopolysaccharide-induced ecto-5'-nucleotidase activity 8561 3.1.3.5 MEDI9447 non-competitive inhibitor 232723 3.1.3.5 Mg2+ 80.9% residual activity at 5 mM 6 3.1.3.5 Mg2+ - 6 3.1.3.5 Mn2+ plasma membrane enzyme 11 3.1.3.5 Mn2+ 0.1 mM activate, 4 mM inhibit, plasma membrane enzyme 11 3.1.3.5 Mn2+ strong, enzyme from glioblastoma cells 11 3.1.3.5 Mn2+ inhibition of cytosolic and membrane-bound enzyme 11 3.1.3.5 molybdate 1 mM, about 15% inhibition 509 3.1.3.5 additional information no substrate inhibition by p-nitrophenyl phosphate 2 3.1.3.5 additional information no product inhibition by 6-thioguanosine 2 3.1.3.5 additional information not inhibitory: EDTA 2 3.1.3.5 additional information not inhibitory: mycophenolic acid 2 3.1.3.5 additional information not inhibited by levamisole 2 3.1.3.5 additional information in vitro and short-term in vivo treatment with fluoxetine and nortriptyline causes no change in activity 2 3.1.3.5 additional information ethanol causes no changes on 5'-nucleotidase activity in vivo 2 3.1.3.5 additional information methanol does not cause any significant alteration on ecto-5'-nucleotidase activity 2 3.1.3.5 additional information not inhibited by lead acetate 2 3.1.3.5 additional information insensitive to levamisole, tetramisole and adenosine 5'-[alpha-beta-methylene]diphosphate 2 3.1.3.5 additional information not inhibited by beta-glycerophosphate 2 3.1.3.5 additional information AMP hydrolysis by ecto-5'-nucleotidase is not affected by levamisole and tetramisole 2 3.1.3.5 additional information no inhibition by sodium orthovanadate 2 3.1.3.5 additional information no inhibition of the enzyme by phosphatase inhibitors. i.e. sodium orthovanadate and sodium fluoride 2 3.1.3.5 additional information not inhibited by haloperidol, sulpiride and olanzapine 2 3.1.3.5 additional information not inhibited by tetramisole 2 3.1.3.5 additional information endogenous inhibitor from rat tissues 2 3.1.3.5 myricetin - 484 3.1.3.5 N-(4-(4-methoxyphenyl)thiazol-2-yl)acrylamide selective inhibitor 251042 3.1.3.5 N-(4-methylcyclohexyl)-1-(2-phenyl-1H-benzimidazole-5-sulfonyl)piperidine-3-carboxamide 17% inhibition at 0.005 mM 232011 3.1.3.5 N-(pyridin-4-yl)furan-2-carboxamide - 232029 3.1.3.5 N-acetylcysteine - 3479 3.1.3.5 N-[4-[5-([2-[2-(4-methoxybenzoyl)hydrazinyl]-2-oxoethyl]sulfanyl)-4-(4-methoxyphenyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-methylbenzene-1-sulfonamide 64% inhibition at 0.005 mM 232110 3.1.3.5 NaAsO2 - 4035 3.1.3.5 NAD+ - 7 3.1.3.5 NADH - 8 3.1.3.5 NADP+ - 10 3.1.3.5 NADPH - 5 3.1.3.5 NaF - 235 3.1.3.5 Ni2+ - 38 3.1.3.5 Ni2+ plasma membrane enzyme 38 3.1.3.5 Ni2+ strong, enzyme from glioblastoma cells 38 3.1.3.5 nitric oxide - 662 3.1.3.5 nortriptyline chronic treatment with 10mg/kg nortriptyline causes a 30% inhibition of AMP hydrolysis 11504 3.1.3.5 nortriptyline - 11504 3.1.3.5 p-chloromercuribenzoate inhibition of cytosolic and membrane-bound enzyme 43 3.1.3.5 Pb2+ - 139 3.1.3.5 Pb2+ plasma membrane enzyme 139 3.1.3.5 pentoxifillin - 138805 3.1.3.5 phenylmethylsulfonyl fluoride inhibition of cytosolic enzyme 257 3.1.3.5 phosphate - 16 3.1.3.5 phosphate inhibition of cytosolic, 5'-IMP-specific enzyme 16 3.1.3.5 PMSF 1 mM, about 40% inhibition 248 3.1.3.5 PO43- weak inhibition 867 3.1.3.5 quercetin - 137 3.1.3.5 Reactive blue - 232726 3.1.3.5 Reactive blue 2 - 4559 3.1.3.5 sertraline enzymatic activity is decreased by the antidepressant sertraline after in vitro exposure 10052 3.1.3.5 SO42- weak inhibition 245 3.1.3.5 sodium 1-amino-4-(2-carboxy-4-fluoroanilino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate PSB-0952 230379 3.1.3.5 sodium 1-amino-4-anilino-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate AB-25 230378 3.1.3.5 sodium 1-amino-4-[(anthracen-2-yl)amino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate PSB-0963 230381 3.1.3.5 sodium 1-amino-9,10-dioxo-4-(phenylamino)-9,10-dihydroanthracene-2-sulfonate - 78973 3.1.3.5 Specific protein inhibitor the periplasmic enzyme has a specific protein inhibitor located in the cytoplasm. The physiological role of the inhibitor is to protect the intracellular nucleotide pool from any cytoplasmic 5'-nucleotidase activity 98749 3.1.3.5 sulfamic acid - 5356 3.1.3.5 Sulfanilic acid - 10787 3.1.3.5 suramin - 704 3.1.3.5 Tartrate 1 mM, about 50% inhibition 762 3.1.3.5 TDP - 694 3.1.3.5 tenascin C strong inhibition 66178 3.1.3.5 tenascin C 75.8% inhibition at 0.025 mg/ml 66178 3.1.3.5 tetramisole 1 mM, 95% residual activity 34600 3.1.3.5 tetrasodium 4-[[4-([4-[(4-amino-9,10-dioxo-3-sulfonato-9,10-dihydroanthracen-1-yl)amino]-2-sulfonatophenyl]amino)-6-chloro-1,3,5-triazin-2-yl]amino]benzene-1,2-disulfonate - 80327 3.1.3.5 thio-IMP substrate inhibition 35452 3.1.3.5 thymidine - 166 3.1.3.5 TTP - 523 3.1.3.5 UDP - 26 3.1.3.5 UTP - 65 3.1.3.5 vanadate 1 mM, about 15% inhibition 233 3.1.3.5 vanillic acid competitive inhibitor, complete inhibition at 0.6 mM 1882 3.1.3.5 vanillic acid - 1882 3.1.3.5 Woodward's reagent K - 22483 3.1.3.5 XTP - 1941 3.1.3.5 Zn2+ 3.0 mM, 75% inhibition of recombinant enzyme, 20% inhibition of native enzyme 14 3.1.3.5 Zn2+ 5 mM, inhibition of both hydrolysis of AMP and ADP 14 3.1.3.5 Zn2+ about 30% enzymatic activity is achieved at 0.05 mM, and the activity drops further to about 15% for 0.5 mM or higher concentrations of Zn2+ 14 3.1.3.5 Zn2+ 2.1% residual activity at 5 mM 14 3.1.3.5 Zn2+ - 14 3.1.3.5 Zn2+ plasma membrane enzyme 14 3.1.3.5 Zn2+ strong, enzyme from glioblastoma cells 14 3.1.3.5 Zn2+ inhibition of cytosolic and membrane-bound enzyme 14